

"Express Mail" Label No. EV 330860046US
Date of Deposit DECEMBER 3, 2003

PATENT
Attorney Docket No.: 020144-001111US
Customer No.: 20350

This is being deposited with the United States Postal Service "Express Mail
Post Office to Address" service under 37 CFR 1.10 on the date indicated
above and is addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Steffen Nock, et al.

Divisional of Application
No.: 09/874,547

Filed: June 4, 2001

For: SCREENING OF PHAGE
DISPLAYED PEPTIDES WITHOUT
CLEARING OF THE CELL CULTURE

Customer No.: 20350

Examiner: Epperson, Jon D.

Art Unit: 1639

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Prior to examination of the above-referenced application, please enter the
amendments as described below.

In order to comply with Requirements for Patent Applications Containing
Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825,
Applicants submit that the computer-readable form in the instant application is identical with the
Sequence Listing filed in Application No. 09/874,547, filed June 4, 2001. In accordance with 37
C.F.R. § 1.821(e), please use the last-filed computer-readable form filed in Application No.
09/874,547 as the computer-readable form for the instant application. A paper copy of the

Sequence Listing from Application No. 09/874,547 is submitted herewith. The information in the paper copy of the Sequence Listing is identical to that which is in the computer readable form submitted on September 28, 2001, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

Amendments to the Specification begin on page 3 of this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 4 of this paper.

Remarks begin on page 6 of this paper.